S64 Hematology and Oncology 2020; 13(1). 2. Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of Adults With Philadelphia Chromosome– Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. JAMA Oncology 2022. 3. Chiaretti S, Bassan R, Vitale A, et al. P353: Forty Months Update of the Gimema Lal2116 (D-Alba) Protocol and Ancillary Lal2217 Study for Newly Diagnosed Adult Ph+ All. HemaSphere 2022; 6: 253-4. 4. Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. The Lancet Haematology 2022. 5. Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood 2016; 128(4): 504-7. 6. Sasaki K, Kantarjian HM, Short NJ, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 2021; 127(15): 2648-56. 7. Ghobadi A, Slade M, Kantarjian H, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood 2022; 140(20): 2101-12. 8. Giebel S, Czyz A, Ottmann O, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the. Cancer 2016; 122(19): 2941-51. 9. Samra B, Kantarjian HM, Sasaki K, et al. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta Haematologica 2021; 144(3): 285-92. 10. Haddad FG, Sasaki K, Issa GC, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American Journal of Hematology 2022. 11. Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia. JAMA Oncology 2017; 3(7). 12. Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. American Journal of Hematology 2019; 94(2): 257-65. 13. Goekbuget N, Dombret H, Zugmaier G, et al. Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months. Blood 2018; 132(Supplement 1): 554-. 14. Zuna J, Hovorkova L, Krotka J, et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia 2022; 36(12): 2793-801. 15. Hovorkova L, Zaliova M, Venn NC, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood 2017; 129(20): 2771-81. 16. Short NJ, Kantarjian H, Ravandi F, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Advances 2022; 6(13): 4006-14. 17. Short NJ, Jabbour E, Macaron W, et al. Ultrasensitive NGS MRD assessment in Ph+ ALL : Prognostic impact and correlation with RT-PCR for BCR::ABL1. American Journal of Hematology 2023. 18. Luskin MR, Stevenson KE, Mendez LM, et al. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults. Blood 2021; 138(Supplement 1): 2305-. 19. Jabbour E, Koller PB, Oehler VG, et al. Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood 2022; 140(Supplement 1): 200-2. 20. Liu W, Liu Y, Zhu Y, et al. The First Report of ThirdGeneration TKI Olverembatinib in Adult Ph/BCRABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease. Blood 2022; 140(Supplement 1): 3266-7. 21. Lv Q, Yu Q, Cao Y, et al. Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation. Blood 2022; 140(Supplement 1): 11688-9.
RkJQdWJsaXNoZXIy MTk3NTQxMg==